►
Description
Open Source Mycetoma Community Monthly Meeting 25th May 2021
The Mycetoma Open Source project (MycetOS) uses an Open Pharma approach to discover new treatments (new chemical entities, or NCEs) for fungal mycetoma (eumycetoma).
The project will drive lead optimization of compounds targeting Madurella mycetomatis, the predominant causative agent of eumycetoma. Using this radically open approach, MycetOS will identify new drug candidates in a transparent and inclusive way.
The project will progress discovery efforts through community-driven, in-kind scientific contributions and a robust, fully transparent online presence. All ideas and results will be published immediately in real time to an open-access database.
All work generated by MycetOS will be published immediately and in real time to the public domain database and thus remain free of the constraints of intellectual property.
Learn more about Mycetoma at WHO website: https://tinyurl.com/WHOMyOS
Learn more about Open Source Drug Discovery: https://opensource.com/life/14/6/international-team-open-sources-search-malaria-cure
GitHub: https://github.com/OpenSourceMycetoma
Twitter: https://twitter.com/mycetos
DNDi: https://dndi.org/research-development/portfolio/mycetos/
C
B
C
A
A
The
presentation,
I
think
so
from
what
I've
heard
sorry
I
couldn't
be
there.
I
was
on
holidays
that
week
had
my
graduation
for
my
phd
but
yeah
they
from
what
I've
heard
they
enjoyed
it.
We
had
labs
on
friday
last
week,
and
I
asked
a
few
of
them
about
that,
and
all
the
demonstrators
and
the
other
teachers
who
are
involved
in
the
topic
said
that
it
went
really
well.
So
thank
you
very
much
for
doing
it.
Yeah
did
you
think,
like
did
you
think
it
went
well?
Did
you
enjoy
it
or.
A
Yeah,
I
was
thinking
that
I'm
like
oh,
let's
make
it
the
easiest
possible
time
and
like
push
it
back
as
far
as
we
can.
So,
if
something
happens
like
we
have
time
but
yeah,
they
all
made
that
well
I'll,
give
an
update,
but
they
all
made
their
compounds
last
week
and
we're
characterizing
them
this
week.
Okay
and
then
we'll
send
them
to
you
who
might
not
make
it
in
time
for
this
year,
but
we'll
see
how
we
go.
F
A
A
G
B
H
I
F
J
F
F
J
F
J
Yeah,
I
actually
thought
yesterday
just
checked
it
again,
so
I
was
thinking
like
kimberly
like
if
there
are
like
time
issues,
so
maybe
we
can.
We
could
make
this
compound
like
adhere
to
ucl,
because
I
have
like
the
substrate,
because
I
just
made
the
first
oxime
product
and
because
we
are,
we
have
like
deadline
in
terms
of
the
larva
season.
So
probably
yes,
yes,
I'm.
F
F
F
H
H
So
you
guys
at
erasmus
our
host
today
and
we
are
minute
takers.
Demisha.
Are
you
able
to
maintain
notes
of
the
meeting
yeah
yeah,
I'm
taking
them
yeah
and
then
just
you
know,
add
those
into
action.
So
the
thing
that
hung
poster
was
really
good.
I
have
to
scoot
I've
been
called
into
immediate
12
30,
so
I've
got
to
go
halfway
through
this,
but
if
you're
on
the
call
demetrius
and
no
doubt
people
have
got
to
do
that,
that'd
be
great.
H
H
We're
thinking
about
about
creating
it,
and
there
was
lots
of
enthusiasm
for
that
across
a
bunch
of
people,
though
there
was
some
potential
clash
that
we
identified
between
this
thing
and
and
something
that
professor
fahal
was
thinking
about
running.
But
I
don't
think
there
is
there's
too
much
of
a
clash.
There.
Dndi
have
said
that
they
are
willing
to
help
us
run
this
thing
and
arrange
it.
H
H
The
icntd
is
all
about
kind
of
building
communities
and
trying
to
get
people
involved
and
doing
things,
and
so
I
because
I
was
I
want
to
try
and
focus
the
session
in
on
what
people
can
do
if
they
want
to
get
involved
somehow
so
try
and
have
that
as
the
main
focus.
But
it
would
be
nice
to
have
an
input
from
our
friends
at
the
cdc
in
the
us.
That
would
be
good
because
they
don't
they
don't
attend
these
meetings.
H
You
know
part
because
they're
not
really
involved
in
it,
but
it
would
be
nice
to
loop
them
in.
If
we
can,
it
seems
okay,
but
we
can
we
can.
We
can
work
out
the
details
later.
I
I
guess
and
make
sure
it's
not
gonna,
be
very
long
event.
I
think
there's
gonna
be
a
few
people.
Gonna
be
talking
about
it,
but
but
just
trying
to
you
know
making
clear
to
what
people
can
do
will
be
great.
C
E
E
F
E
E
H
J
E
The
good
thing
is
that
they
were
active
against
both
and
the
fem
er.
The
fenery
moles
were
not.
We
tested
recently
the
fem,
the
fenery
malls
against
falsiforespora
senegalensis
and
they
were
not
active.
The
asos
were
not
active
either,
though
at
the
concentrations
test
we
usually
test,
so
they
do
seem
to
have
higher
mics
towards
51
inhibitors.
E
On
the
other
hand,
the
binofin
was
very
active
against
false
forespora
synagogue
lenses,
but
not
that
active
against
modular
mice,
tomatoes.
So
it
seems
that
there
really
are
differences
in
susceptibility
and
since
currently,
the
diagnostics
is
not
up
to
date
and
we
need
to
have
some
selection
of
compound
series.
Maybe
this
is
a
good
way
also
to
make
sure
that
those
two
main
causative
agents
are
active
in
wilson's
screening
of
the
pandemic
box.
We
also
saw
that
when
false
forespore
senegalensis
was
active,
usually
the
other
causative
agents
of
the
plios
parallels
were
active
as.
F
C
C
Yeah
there
was
a
a
thing
in
korea
last
year
or
the
year
before
last,
where
a
doctor
recommended
for
benders
or
for
cancer
treatment,
I
mean
forbenzazole
is
useful
to
treat
cancer
in
dogs,
but
I
think
she
recommended
it
for
benders
or
for
to
treat
cancer
in
humans,
but
that
didn't
turn
out
well,
that
was
on
the
news
and
for
bendezo
carbendazim.
They.
The
compounds
that
we
found
were
active
against
mother
elements,
tomatoes,
but
they're.
Actually,
I
would
say
benzemidazole
carbamates.
C
F
F
F
F
D
D
H
H
E
A
G
I
H
F
C
I
have
attached
a
screenshot
of
the
table
that
I've
made
with
all
the
benzemidazoles.
You
know
three
boxes,
pathogen
statuses
and
pandemic
box
they're
in
the
chat
and
then
the
next
one
is
some
other
information
pathogen
for
the
pathogen
and
pandemic
boxes.
We
are
able
to
get
the
structures
from
the
ndi
and
readily
available,
but
for
the
status
boxes.
A
C
C
E
No
in
the
status
box,
the
smileys
are
not
given,
because
otherwise
it
would
be
not
that
difficult.
I
guess
to
these
were
compounds
still
in
development
or
halted.
Therefore,
this
box
was
not
given
to
everybody,
but
we
were
given
a
copy
and
we
were
lucky
with
that
compound
you're
working
on
so
the
amount,
a
minor
thiazole,
because
they
were
able
to
disclose
the
information
behind
that
compound.
H
E
So
maybe
it's
good
to
focus
on
those
which
are
at
least
active
against
a
causative
agent,
which
is
also
very
prevalent,
but
then
maybe
in
western
africa.
Although
my
adrenaline,
my
estimate,
is
still
the
very
most
important
causative
agent
and
it's
still
very
important
to
focus
on
that.
But
just
as
a
precaution,
let's
include
fossil
fuels
for
screening
as
well,
just
just
to
make
sure
that
the
compounds
we
identify
are
active
against
that
one
as
well.
E
Yes,
we
for
now
we
screened
against
four
spores
syngalences,
because
what
we
found
out
well,
you
can
roughly
divide
the
causes
of
agents
into
two
groups.
One
are
the
solidarians
where
modular
mastermates
belongs
to
the
others.
Are
the
pleosporalis
one
of
majority
of
the
other
causative
agents
belongs
to
so
that's
a
little
bit
comparing
human
to
fish
and
that
what
we
saw
was
that
false
phosphorus
cingulances
behaves
roughly
the
same
as
the
other
causative
agents
belonging
to
the
pleiosporalis.
E
So
that's
why
we
selected
that
one,
because
it
was
the
most
common
of
that
group.
We
have
multiple
isolates
of
that
one,
but
we
do
have
isolates
of
the
other
ones
as
well.
Metacopter's
romurai
also
belongs
to
this
group,
but
in
general
it's
very
resistant
to
any
antifungal
agent.
So
so
far
in
the
screening
wilson
did.
E
I
E
E
A
A
A
So
basically,
we
have
the
hit
compound
at
the
top
and
then
as
part
of
the
training.
The
demonstrators
have
also
done
this
synthesis,
so
we
got
them
to
make
their
own
compounds
as
well.
So
we've
moved
the
nitrogen
around
the
ring
and
removed
the
nitrogen,
and
then
the
students
have
worked
on
these
other
10
compounds.
So
we'd
already
done
the
nitrogen
at
the
two
and
the
three
position,
so
we've
moved
it
to
the
four
and
then
we've
done
substitution
at
the
two
three
and
four
positions
with
chlorofluoro
and
the
methoxy.
A
A
A
H
A
Yeah,
so
some
of
them
are
particularly
because
they
have
the
four
methyl
group
on
the
red
side
of
the
ring
there.
A
bunch
of
them
have
sort
of
been
made
with
the
two
purel
group,
or
just
without
the
nitrogen
at
all.
But
with
that
methyl
group,
a
bunch
of
them
are
pretty
novel,
but
some
of
them
also
aren't
so.
F
B
F
A
A
F
H
A
Yeah,
so
if
we
get
all
the
characterization
done
on
friday
like
I
just
want
to
make
sure
that
they
actually
are
what
they
are
and
we're
going
to
do,
hplc
as
well,
so
I
want
to
check
the
purity
because
some
of
them
we
have
just
got
the
solid
and
we
haven't
done
a
column,
so
we
might
have
to
do
a
column
if
the
purity
is
less
than
95
or
something.
So
I
just
want
to
double
check
those
things
and
then,
if
that's
all
good
to
go
like
I'll
ship
them
straight
away,
are.
A
J
A
I
J
Okay,
so
a
quick
update
like
on
the
general
chemistry,
so,
first
of
all,
I
one
of
the
recent
compounds
that
I've
made
well
not
actually
made,
but
like
do
you
protect
the
the
dm
23
6
phenomenal
that
we
have
already
tested.
So
now
we
have
a
d
protected
version
as
well
as
a
tfa
salt.
So
that's
like
the
latest
addition
to
our
library.
J
So
we
still
need
to
just
can
make
some
conclusions
about
that
compound
like
and
what
sort
of
results
it
will
generate
in
this
altered
version
with
regards
to
oximes.
So
basically,
I
made
the
ketone
intermediate
and
then
I
use
bismuth
oxide
to
make
the
final
oxygen
compound
and
probably
I'll
be
using
the
same
procedure
with
the
fluorcam
substrate
as
well.
J
J
F
J
Yeah,
so
that
that's
with
regards
to
rock
slimes
coming
back
to
phenomenals
as
well,
so
we
were
thinking
about
like
what,
based
on
the
results
that
we
got
from
the
screening
campaign
like
from
the
last
screening
campaign,
so
the
m71
was,
is
now
the
second
most
active
compound
like
in
bible
from
the
entire
library.
So
I
thought,
like
maybe
we
can
elaborate
on
this
a
bit
more
so
with
what
we
would
like
to
propose
is
like
one
of
the
new
analogs,
probably
is,
would
be
the
pyrologine
as
well.
J
I
also
thought,
maybe
to
elaborate
on
the
m71
and
propose
like
this
substrate
as
well,
though
matt
was
like
a
bit
skeptical
about
this
because
he
said
like
the
night
trial
apparently
is
too
far
away,
but
again,
like
we
don't
know
the
exact
mechanism
of
action.
So
maybe
this
should
still
go.
So
I
I
don't
know
the
exact
log
d
value,
because
we
need
a
task
band
to
generate
this
with
the
start
drop
software
as
well.
But
we
would
definitely
do
the
paralleledine
as
latest
edition
as
well.
J
J
Yes,
so
and
basically
in
terms
of
like
the
what
we
have
like
in
total,
like
for
the
upcoming
screening
campaign,
so
those
compounds
like
highlighted
in
green
already,
dm
27
and
28
has
been
synthesized
before,
but
it
hasn't
been
tested
in
the
previous
screen
campaign.
I'm
not
entirely
sure
whether
it's
in
order
for
them
or
still
in
the
lab.
I
will
double
check
that,
but
those
already
so
by
that
by
the
end
of
ju
by
the
first
of
july,
we'll
have
like
some
extended,
like
library,
heat
tests.
J
J
J
F
Compound
with
that
methyl
removed,
so
it's
just
the
two
rings
and
then
it's
four
for
chloro
on
the
ring.
So
you
could
order,
try
that
and
I
would
save
you.
It
wouldn't
be
the
exact
compound
I
proposed
to
kim,
but
it
would
be
close
to
close
enough
to
it
that
I
think,
would
be
fine
just
to
order
that
from
fluorocam
and
do
the
final
step
of
the
business.
J
Season
but
again,
like
I
mentioned
before,
that,
probably
phenomenals
like
at
this
stage
are
not
the
best
option,
because
they're
not
active
against
multiple
strengths,
but
still
we
would
like
to
maybe
slightly
elaborate
like
on
this
active
that
we
have
like
from
from
the
ucl
screen
from
the
use
of
ecl
library.
Sorry,.
E
J
J
A
J
The
only
problem
we
have
currently
is,
I
don't
know
the
log
d,
because
we
bend
uses
start
drop
and
we
agree
that
we
would
use
the
same
software
because
different
software's
like
generate
like
there's,
a
deviation
like
in
the
results.
It's
just
like
for
consistency,
reasons.
We
need
to
I'll,
probably
ask
him
yeah.
A
I
think
it's
okay,
though,
to
get
like
an
estimate
to
see
whether
it
sort
of
fits
in
with
the
trends
that
we're
seeing
and
whether
it's
a
compound
we
want
to
make
or
not
and
then
like
getting
the
exact
one.
I
think
it's
okay
for
now
and
then
yeah
like.
If
you
decide
you're
gonna
make
it,
then
you
can
ask
him,
because
we
can't
ask
him
every
time
we
come
out
with
one
structure
like
but
yeah.
J
A
A
F
F
C
J
C
J
We
planned
the
whole
work
based
on
that
deadline,
so
I've
been
keeping
like
that
first
of
july,
before
the
first
of
july
deadline
in
my
head,
so
yeah.
So
that's.
Why,
like
I
took
like,
for
instance,
like
one
compound
like
from
the
mega
throughout
like
from
the
master
list,
and
we
propose
like
two
new
ones,
so
definitely
want
to
make
those
at
least
yeah
got
it.
J
So
currently,
what
I've
been
doing
like
in
in
the
last
week
is
just
like
we're
talking
on
the
arrow
halide
and
doing
the
peperazine
scaffold
as
well,
because
I
don't
have
that
one,
but
then
it
should
be
absolutely
a
quick
process.
So
I'm
pretty
certain
like
that.
We'll
get
those
compounds
in
time
and
the
green
ones
are
ready,
even
though
the
first
lock
time
is
already
just
finalizing
the
characterization
yeah
okay,
so
they
are
like.
J
A
C
A
E
E
J
Okay,
that's
good
to
know
because
we
see
actually
I
was
we
were
planning
like
by
the
end
of
june,
but
probably
we
can
send
those
at
least
the
ones
that
we
got.
It's
not
a
problem,
yeah,
we'll
just
double
check
that
they're
stable
we'll
do
the
nmrs
quickly
just
to
see
that
everything's.
So
candid
sure,
thanks
dimitri.
C
I
think
I
mean
do
you
have
any
updates
more
updates
on
your
side,
or
is
that
it
that's
it?
I
think
that's
it.
Okay,
do
we
have
anything
that
we
would
like
to
other
topics
or
subjects
that
we
would
like
to
touch
upon
for
the
next
meeting,
for
example,
because
I
don't
think
we
have
much
tasks
for
the
next
meeting.
A
C
J
If
yeah
I
asked
this
before,
but
I'm
so
sorry,
if
we're
asking
this
again,
is
the
reason
why
dm
25
didn't
proceed
in
vivo
because
it
had
like
those
like
relatively
good
values.
So,
for
example,
like
minimum
inhibitory,
concentration
was
the
same
as
like
with
dm7,
which,
which
is
like
the
second
most
potent
compound.
C
C
C
C
J
E
Yeah,
that's
because
here
you
only
display
the
125
and
if
you
look
at
your
table,
that's
quite
consistent
where
the
mic
50
would
be.
But
of
course
it's
not
only
this
compounds
with
screen,
it's
the
old,
the
whole
picture
of
all
compounds,
and
therefore
only
those
with
an
mic
of
below
eight
were
chosen.
E
C
E
E
J
You
mean
yes
yeah,
because
there's
also
like
one
of
the
non-tested
analogs,
so
we
elaborate
like
on
on
this
one
actually
by
extending
like
the
ring
the
hydrocarbon
chain
slightly,
but
this
has
not
been
tested
yet.
So
it's
like
interesting
to
see
like
what
sort
of
results
you
will
come
up
with
and
maybe
then
we
can
decide
like
whether
it's
one
okay,
we
will
have
have
a
look
at
that
as
well.
Yeah.